Boehringer more than doubles size of venture fund

German pharma major Boehringer Ingelheim has increased the size of its corporate venture fund to 250 million euros ($301 million).

Previously, the privately-held company had invested 100 million euros into the Boehringer Ingelheim Venture Fund (BIVF). The additional funds will be used to invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immuno-oncology among others, as well as growing the portfolio in the USA and opening doors for the BIVF in digital health. There will be a doubling of the number of investment managers.

Frank Kalkbrenner, corporate vice president and head of the BIVF, said: “We at the BIVF are inspired by the opportunity to increase investments and work across some of the most promising areas of biomedical research to date.